CClinicalTrials.gg
SuspendedNCT03871400Updated Oct 19, 2020

The NanoStrand Clinical Study

An interventional study of Anterior cervical discectomy and fusion in Disc Degeneration;Cervical, sponsored by SeaSpine, Inc.. Suspended at 11 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-10-19.

Sponsored by SeaSpine, Inc. · Not applicable, Interventional, and Other

Why this study was suspended
Study halted prematurely and will not resume; participants are no longer receiving intervention due to coronavirus pandemic and unexpected enrollment delays.

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Nov 2018, registered Mar 2019).
Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

A prospective, multi-center, randomized, self-controlled, single-blinded, clinical study evaluating the NanoMetalene implant as compared to the PEEK and allograft implants in ACDF for the treatment of cervical degenerative disc disease (DDD).

Read the detailed description

PEEK: Polyetheretherketone ACDF: Anterior cervical discectomy and fusion

02

Conditions studied

  • Disc Degeneration;Cervical
03

In context

Intervertebral Disc Degeneration

464 studies on the registry are indexed under Intervertebral Disc Degeneration; 98 are open to participants now.

This study's enrollment of 18 is below the median of 60 across 261 interventional studies indexed under Intervertebral Disc Degeneration.

Browse Intervertebral Disc Degeneration studies →

Lead sponsor

SeaSpine, Inc. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Cervical degenerative disc disease
  • Requires primary spinal fusion from C3-C7
  • Minimum of 6 weeks of non-operative treatment
  • Signed informed consent form

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled type I or II diabetes mellitus
  • Morbid obesity
  • Documented history of alcohol or drug abuse
  • Fever or leukocytosis
  • Current systemic infection
  • Active malignancy and/or current chemotherapy
  • Known history of osteoporosis
  • Prior fusion or total disc replacement at the operative level or an adjacent level
  • Infection of the operative site
  • Use of implants from other systems
  • Pregnancy
  • Participation in another research study
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
18 participants (actual)

Study arms

  • Other
    NanoMetalene/PEEK

    Procedure: Anterior cervical discectomy and fusion

  • Other
    NanoMetalene/Allograft

    Procedure: Anterior cervical discectomy and fusion

Interventions

  • ProcedureAnterior cervical discectomy and fusion

    primary, 2-level, contiguous

06

What researchers measure

Primary outcomes

  1. Proportion of cervical spinal levels for NanoMetalene vs PEEK interbody implants that have achieved fusion as determined by Computed Tomography (CT) analysis

    Proportion of cervical spinal levels for NanoMetalene vs PEEK interbody implants that have achieved fusion as determined by Computed Tomography (CT) analysis

    Time frame: 12 months

Secondary outcomes

  1. Secondary CT Analysis: PEEK

    Proportion of cervical spinal levels for NanoMetalene vs PEEK interbody implants that have achieved fusion as determined by Computed Tomography (CT) analysis

    Time frame: 12 months

  2. Secondary CT Analysis: Allograft

    Proportion of cervical spinal levels for NanoMetalene vs Allograft implants that have achieved fusion as determined by Computed Tomography (CT) analysis

    Time frame: 12 months

  3. Secondary X-Ray Analysis

    Proportion of cervical spinal levels for NanoMetalene vs PEEK and Allograft implants that have achieved fusion as determined by x-ray analysis

    Time frame: 24 months

  4. Clinical Outcomes: NDI

    Improvement of clinical outcomes (NDI) for all enrolled patients. Improvement is a reduction of scores for all clinical outcomes. Results will be shown as change from baseline to 24 month follow-up. The NDI is an index derived from the Neck Disability Index Pain Questionnaire used by surgeons, clinicians and researchers to quantify disability for neck pain. Scores are from 0-100 and a lower score represents a better score.

    Time frame: 24 months

  5. Clinical Outcomes: VAS Arm

    Improvement of clinical outcomes (VAS Arm) for all enrolled patients. Improvement is a reduction of scores for all clinical outcomes. Results will be shown as change from baseline to 24 month follow-up. The visual analogue scale (VAS) is a commonly used outcome measure for research studies. It is presented as a 100-mm horizontal line on which the patient's pain intensity is represented by a point between the extremes of "0"/no pain at all" and "100/worst pain imaginable." The study in this scale is used for the worst arm pain. A lower score represents a better score.

    Time frame: 24 months

  6. Clinical Outcomes: VAS Neck

    Improvement of clinical outcomes (VAS Neck) for all enrolled patients. Improvement is a reduction of scores for all clinical outcomes. Results will be shown as change from baseline to 24 month follow-up. The visual analogue scale (VAS) is a commonly used outcome measure for research studies. It is presented as a 100-mm horizontal line on which the patient's pain intensity is represented by a point between the extremes of "0"/no pain at all" and "100/worst pain imaginable." The study in this scale is used for neck pain. A lower score represents a better score.

    Time frame: 24 months

07

Study locations

11 sites
  • Barrow Brain and Spine
    Phoenix, Arizona 85013, United States
  • University of California, San Diego
    La Jolla, California 92093, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • UCLA Health
    Santa Monica, California 90401, United States
  • University of Colorado Hospital
    Aurora, Colorado 80045, United States
  • Spine Colorado
    Durango, Colorado 81301, United States
  • Emory
    Atlanta, Georgia 30324, United States
  • Hughston Clinic
    Columbus, Georgia 31909, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • OrthIndy
    Indianapolis, Indiana 46278, United States
  • Henry Ford
    Jackson, Michigan 49201, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03871400
Lead sponsor
SeaSpine, Inc.
Responsible party
Sponsor
First posted
Mar 12, 2019
Start date
Nov 18, 2018
Primary completion
Jun 15, 2020
Completion
Jan 30, 2021 (estimated)
Last update
Oct 19, 2020

Study contacts

Khalid Abbed, MD
principal investigator · Yale University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion